Evidence method
Level · gp.fundamentals.debt_to_revenue
1049.93% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
TCRX · Jun 30, 2025
TScan Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-25-106919General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
41.58% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-1081.50% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
473.88% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-1256.60% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
1060.92% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
106.40% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History11 statesHistory building
Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20267/7 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 1482.36%
- Current
- 1049.93%
- Delta
- -432.42%
- Previous
- 70.57%
- Current
- 41.58%
- Delta
- -28.99%
- Previous
- -1731.28%
- Current
- -1081.50%
- Delta
- 649.77%
- Previous
- 283.57%
- Current
- 473.88%
- Delta
- 190.31%
- Previous
- -1669.74%
- Current
- -1256.60%
- Delta
- 413.14%
- Previous
- 1372.09%
- Current
- 1060.92%
- Delta
- -311.16%
- Previous
- 157.25%
- Current
- 106.40%
- Delta
- -50.85%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · TCRX Fundamental State →Has State · TScan Therapeutics, Inc. →Transitioned To · TCRX Fundamental State →Transitioned To · TCRX BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · TCRX CAPEX_INTENSITY_DECREASED →Transitioned To · TCRX CASH_GENERATION_INCREASED →Transitioned To · TCRX GROWTH_INCREASED →Transitioned To · TCRX PROFITABILITY_INCREASED →Transitioned To · TCRX R_AND_D_INTENSITY_DECREASED →Transitioned To · TCRX SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.